The Neurology Centre of Toronto (NCT), located in a midtown neighborhood and owned by Numinus Wellness Inc. (OTCQX: NUMIF), is offering ketamine-assisted therapy for patients with neurologic conditions diagnoses.

Numinus is focused on delivering evidence-based, innovative and safe psychedelic-assisted therapies for mental health disorders. The treatment’s transformational goal is to heal rather than manage symptoms emerging from depression, anxiety, trauma, pain and substance use.

On the new proposal, Numinus’ vice president Dr. Evan Lewis said that after evaluating NCT’s existing infrastructure, client base and practitioners, the company considered the facility to be “highly suitable” for …

Full story available on Benzinga.com